Role of VAD in the initial treatment of multiple myeloma
- 15 November 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (10) , 3674-3675
- https://doi.org/10.1182/blood-2005-07-2610
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Multiple myeloma: the death of VAD as initial therapyBlood, 2005
- Treatment of Plasma Cell Dyscrasias With Thalidomide and Its DerivativesJournal of Clinical Oncology, 2003
- Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patientsBone Marrow Transplantation, 2003
- Effect of complete response on outcome following autologous stem cell transplantation for myelomaBone Marrow Transplantation, 2000